Compare LTC Properties Inc (LTC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Tango Therapeutics Inc. — how do they compare? LTC Properties Inc trades at $42.66 (market cap $2.33B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and LTC Properties Inc pays a 5.28% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 89 Days and Tango Therapeutics Inc. for 0 Days on average.
| LTC | TNGX | |
|---|---|---|
Market Cap | $2.33B | $3.74B |
Volume | 502,391 | 3,438,781 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $32.90 |
52-Week Low | $34.04 | $7.50 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $3.07B | $2.76B |
Dividend Yield | 5.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties (NYSE: LTC) trades at $42.91, down 0.33% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $49.67 implying 16% upside. The REIT reported Q2 2026 EPS of $0.56, beating expectations, and maintains strong profitability with a 38.93% net income margin. Recent news highlights accelerated SHOP portfolio growth with $160 million in acquisitions and consistent monthly dividends of $0.19 per share.
The outlook is positive due to demographic tailwinds in senior housing, but risks include rising interest rates impacting financing costs and execution challenges in portfolio transition. Analyst sentiment is mixed with 32% buy ratings, reflecting balanced risk-reward near current levels.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
